Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 May 3;10:411. doi: 10.3389/fgene.2019.00411

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2019 Rodríguez, Naveja, Torres, García de Teresa, Juárez-Figueroa, Ayala-Zambrano, Azpeitia, Mendoza and Frías.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

WIP1 is required for DDA in FA pathway deficient cell lines. (A) The ovarian cancer cell line TOV21G+EV deficient in FANCF shows sensitivity to GSK2830371. (B) The MCF7 cell line has been previously shown to be sensitive to WIP1 inhibition, whereas the HeLa cell line has been reported to be non-sensitive. (C) WIP1 inhibition with GSK2830371 sensitizes the TOV21G+EV ovarian cancer cell line to Carboplatin. (D) WIP1 inhibition with GSK2830371 sensitizes the TOV21G+EV ovarian cancer cell line to Olaparib. (E) WIP1 inhibition with GSK2830371 sensitizes the EUFA316+EV cell line to MMC.